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A B S T R A C T
The purpose of this study was to design an innovative topical ointment containing
betamethasone dipropionate loaded nanostructured lipid carrier (BD-NLC) for the treat-
ment of atopic dermatitis (AD). BD-loaded NLC was produced with precirol ATO 5 and oleic
oil (OA) by melt emulsification method. Effects of surfactant concentration, amount of solid
lipid and liquid lipid on skin retention and skin penetration were investigated by in vitro per-
cutaneous permeation experiment. The optimized BD-NLC showed a homogeneous particle
size of 169.1 nm (with PI = 0.195), negatively charged surface (−23.4 mV) and high encapsu-
lation efficiency (85%). Particle morphology assessed by TEM revealed a spherical shape. In
vitro skin permeation study was carried out to investigate the percutaneous behaviors of W/O
ointment with BD-NLC and Carbopol emulgel ointment with BD-NLC. W/O ointment with BD-
NLC showed high skin retention (35.43 μg/g) and low penetration (0.87 μg/ml). In vitro drug
release studies were carried out to demonstrate the drug releasing properties of the two oint-
ments. W/O ointment with BD-NLC showed an advantage for skin retention as it was better
for drug release. The tissue distribution test suggested that BD distribution was
skin > muscle > blood. Self-made topical ointment in mice showed no skin irritation.The animal
experiments indicated that BD-loaded NLC ointment was effective and safe for topical use.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The nature of skin, especially the bulk of stratum corneum (SC)
is the main physical barrier of transdermal drug delivery system
(TDDS) [1].The approaches to enhance drug permeation include
chemical techniques based on chemical penetration enhanc-
ers (CPEs) [2], and physical techniques such as ultrasound [3],
iontophoresis [4], and microneedles [5,6]. CPEs can enhance skin
permeability of drugs. Though CPEs are commonly used in en-
hancing drug penetration, they are limited by safety concerns,
such as skin irritation [7]. The overall effectiveness of
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physical strategies is as strong as that of CPEs, but their in-
convenient use and high cost limit their use. Recently, lipid
nanoparticles have been introduced into topical application to
improve skin drug delivery. Many researches have been con-
ducted on this novel strategy, indicating remarkable results
[8–10].
Nanostructured lipid carrier (NLC) is new generation of lipid
nanoparticles, which is an aqueous colloidal dispersion com-
posed of blended solid lipids and liquid lipids (oils) [11]. It was
recognized as a promising drug carrier system for topical ap-
plication because of its improving skin penetration properties
[12]. The applications of NLC in the treatments of skin dis-
eases such as skin dermatitis, psoriasis and inflammations were
reported in the literature [12,13]. For TDDS, molecular proper-
ties of active compound are crucial for transdermal potential.
For example, when the molecular weight is >500 Da, it is con-
sidered that the drug cannot go through skin. So far, the
mechanism of the improved skin penetration of NLC is not yet
clear. Compared with other vehicles such as creams, tinc-
tures, and emulsions, NLCs possess such advantages as
controlled drug release, protection of active compounds and
negligible skin irritation.Moreover, the small particle sizes ensure
that the nanoparticles are in close contact with the stratum
corneum (SC), thus promoting the amount of active com-
pound which penetrates into the skin [11]. Lipid nanoparticles
used as a carrier system for topical delivery of several drugs
including clotrimazole, prednicarbate, betamethasone 17-
valerate and podophyllotoxin were investigated and they were
reported to have a skin targeting potential [14,15].
Atopic dermatitis (AD) is a kind of skin dermatitis. Topical
glucocorticoids are recommended for acute exacerbations of
atopic dermatitis [16]. Betamethasone Dipropionate (BD), a kind
of glucocorticoid, is mainly used for the treatment of AD [17,18].
As we know, glucocorticoids can bring many side effects. Nor-
mally, short-term treatment, and reducing the amount of drug
are recommended in the clinic [17]. Hence, it is necessary to
improve the drug skin retention and reduce the penetrating
amount into systemic circulation in topical application, which
will decrease the risk of a systemic side effect.
In the present study, NLC was investigated as a drug de-
livery system for BD. Particle size, zeta potential, morphology
and the entrapment efficiency of NLC dispersions were char-
acterized. It would be convenient for topical use when NLC
dispersions are combined with ointment. Therefore, W/O oint-
ment and Carbopol emulgel ointment were prepared as topical
ointment matrix, respectively. Meanwhile, in vitro drug release
studies were carried out to demonstrate drug release proper-
ties of the two ointments. Tissue distribution experiment in
mice was conducted finally to evaluate the skin retention effect
for reducing the penetration amount into systemic circula-
tion. Skin irritation test was carried out to demonstrate whether
NLC could reduce the risk of skin irritation.
2. Materials and methods
2.1. Chemistry and materials
Betamethasone Dipropionate (BD) (purity >99%) was pro-
vided by Wuhan Dahua Pharmaccutical Co., Ltd. (Wuhan, China).
Oleic oil (OA), Tween 80, Span 80, liquid paraffin and stearyl
alcohol were obtained by Tianjin Bodi Chemical Co., Ltd. (Tianjin,
China). Carbopol 971 was from Lubrizol Co. Ltd. (Ohio, USA).
White vaseline, iso-propyl alcohol and isopropyl palmitate (IPP)
were provided by Shandong Damao Chemical Reagent Factory
(Shandong, China), Shandong Yuwang Industrial Co., Ltd. (Shan-
dong, China), and International Specialty Products Inc. (New
Jersey, USA), respectively. Transparent cellophane membrane
and sephadex G-50 were from Shangyu cellophane Co., Ltd.
(Zhejiang, China) and Pharmacia & Upjohn Company (New
Jersey, United States), respectively. Precirol ATO 5 was a gen-
erous gift from Gattefossé (Lyon, France). All other chemicals
used were of analytical grade and commercially available.
2.2. Animals
Rabbits (male, 1.5–2.0 kg) and KM mice (male, 20 ± 2.0 g) used
in the experiments were purchased from the Experimental
Animal Center of Shenyang Pharmaceutical University
(Shenyang, China). The experiments were performed in accor-
dance with the guidelines for animal use published by the Life
Science Research Center of Shenyang Pharmaceutical University.
2.3. Preparation and characterization of BD loaded NLC
2.3.1. Preparation of BD loaded NLC
BD-loaded NLC was produced using melt emulsification com-
bined with ultra-sonication technique as reported previously
[19]. In brief, Precirol ATO 5 and OA (3% in total, w/v) were
blended under gentle stirring in water bath at 85 °C to form
the lipid phase. Successively, BD (0.05%, w/v) was added in the
lipid phase until completely dissolved. Meanwhile, Tween 80
was dissolved into distilled water corresponding to 10 ml at
85 °C and added dropwise to the lipid phase, with moderate
magnetic stirring for 7 minutes. The coarse emulsion was
further subjected to an ultrasonication procedure through a
probe-type sonicator (Scientz-II D, NingBoXinZhi, Ningbo, China)
for 72 s under 400 W ultrasonic output power to reduce the par-
ticle sizes of emulsions to nano range. The obtained
nanoemulsions were cooled down in an ice-water bath to form
the NLC rapidly. The total volume of BD-NLC suspensions were
supplemented by adding distilled water to 10 ml.
2.3.2. Characterization of the NLC dispersion
Mean particle size (Z-average), dispersity index (PI) and zeta
potential of BD-NLC suspensions were determined by photon
correlation spectroscopy (PCS) (Malvern Nanosizer ZS90,Worces-
tershire, UK) for characterizing the width of distribution and
the stability of the product under 25 °C. For particle size and
PI detection, the PCS was performed at a detection angle 90 °C.
Before the detection, each sample was diluted 100 folds with
distilled water. Each value was measured in triplicate.
The shape and surface morphology of BD loaded NLC was
observed by transmission electron microscopy (TEM, JEM-
1200EX,Tokyo, Japan). A drop of NLC suspensions diluted 5 folds
was dispersed on a 200-mesh copper grid. After the exces-
sive water was removed with filter paper, the sample was
negatively stained with 2.5% phosphotungstic acid for 4 min
for observing.
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2.3.3. Determination of NLC entrapment efficiency (EE)
Non-encapsulated BD was separated from nanoparticles by size
exclusion chromatography (SEC) using the mini-column cen-
trifugation method. Briefly, 5.0 ml disposable syringe barrels
were plugged with cotton filters and filled with Sephadex G-50
Medium. After spinning the column at 2000 rpm to remove the
liquid, BD-NLC suspensions (0.5 ml) were added onto the top
of the gel bed.The columns were centrifuged again at 2000 rpm
for 3 min to expel the void volume containing the nanoparticles
and the eluates were kept for assaying. The eluent (distilled
water, 1.0 ml) was loaded onto the micro column and centri-
fuged for 1.0 min (2000 r/min).This step was repeated forth until
all nanoparticles had come off the column.The eluent was col-
lected together and diluted to 10 ml. BD in the diluted sample
(1.0 ml) was dissolved by methanol and diluted to 5.0 ml. The
sample was filtered through a 0.45 μm syringe filter. Finally, the
drug concentration in the eluates was determined by UV-
2800 spectrophotometer (Unico Instrument Co., Ltd., Shanghai,
China). The concentration of BD was marked with C1.
BD-loaded NLC dispersions (0.5 ml) were diluted by dis-
tilled water to 10 ml. The diluted sample (1.0 ml) was dissolved
by methanol and diluted to 5.0 ml. The sample was filtered
sucessfully through a 0.45 μm syringe filter. The concentra-
tion of BD was detected by the same method and marked with
C2. EE of the sample was calculated by Eq. 1:
EE C C% %= ( ) ×1 2 100 (1)
2.4. Preparation of NLC ointment
Generally, BD-loaded NLC dispersions can be incorporated into
ointment for topical use. Carbopol emulgel ointment and W/O
ointment were investigated as matrix of the topical NLC oint-
ment here.
The formulation of Carbopol emulgel ointment was labeled
in Table 1. Carbopol 971 was dispersed into distilled water 24 h
before the test. The pH of the sample was adjusted to 7.0 by
triethanolamine. Finally, the mixture of Span 80 and IPP was
dropped to Carbopol dispersion under agitation.
The formulation of W/O ointment was labeled in Table 2.
The oil phase of W/O matrix contained stearyl alcohol, liquid
paraffin, white vaseline, and Span 80. The oil phase and dis-
tilled water were both heated in 80 °C water bath. Then the
oil phase was dropped into distilled water under magnetic stir-
ring. Finally, the matrix was cooled down to room temperature.
BD-loaded NLC dispersions (10 ml) were incorporated into
the two topical vehicles under homogeneous stirring,
respectively.
2.5. In vitro skin permeation experiment
2.5.1. Preparation of rabbit skin
The process of the preparation and storage of the rabbit ab-
dominal skin were based on an ordinary method published in
a transdermal report [20,21]. The details were described here.
The rabbits should be anesthetized with urethane (20%, w/v,
i.v.). The electric clipper and razor were used to remove the ab-
dominal hair. The skin without hair (full thickness skin here
including epidermis with SC and dermis) was then excised from
the shaved abdomen. The subcutaneous fat was removed care-
fully from the obtained skin with a surgical scissor. Finally, the
skin was washed immediately with phosphate-buffered saline
and stored at −70 °C. The skin samples were used within 1
month, which is about the time when the normal activity of
the stratum corneum (SC) layer is still preserved.
2.5.2. In vitro skin permeation
Franz vertical diffusion cells were used in the in vitro skin per-
meation experiment of BD-loaded NLC dispersion.The effective
diffusion area of the diffusion cell was 1.77 cm2. The rabbit ab-
dominal skin was situated between the donor chamber and
the receiver chamber.The mixture of phosphate-buffered saline
(PBS, pH 7.4) and iso-propyl alcohol (7:3, v/v) was used as a re-
ceiver liquid. The volume of the receiver liquid was 7.0 ml. The
media was stirred at about 600 rpm, and the temperature of
receiver chamber was maintained at 32 °C by a circulating-
water jacket during the whole experiment. NLC sample (2.0 ml)
was applied into the donor chamber. The permeation experi-
ment lasted for 24 h.
After 24 h skin permeation, the receiver medium was
collected and centrifuged at 16,000 rpm for 5 min. The con-
centration of BD was determined by HPLC.
The skin sample was taken off from the Franz cell and wiped
off with cotton swabs to remove the excessive drug on the
surface. The sample was weighed precisely and cut into small
pieces. Ethyl acetate (1.0 ml) was added into skin sample and
sonicated for 20 min to extract BD from skin. The concentra-
tion of BD in ethyl acetate was determined by HPLC. The drug
retention in the skin was expressed as microgram of BD per
gram of skin weight (μg/g).
2.6. In vitro drug release
In vitro drug release behaviors of Carbopol emulgel ointment
with BD-NLC and W/O ointment with BD-NLC were investi-
gated with Franz vertical cells.The receiver liquid was the same
as the in vitro skin permeation experiment in Section 2.5.2.
Transparent cellophane membrane was used as permeation
barrier, and the ointment (2.0 g) was applied into each donor
chamber. The sampling time points were designed as 0, 4, 6,
Table 1 – Formulation of Carbopol emulgel ointment
matrix.
Carbopol 971 0.75%
Span 80 0.75%
IPP 3.5%
Distilled water 95%
Total amount 20.0g
Table 2 – Formulation ofW/O ointment matrix.
Stearyl alcohol 3%
Liquid paraffin 34%
White vaseline 30%
Span 80 3%
Distilled water 30%
Total amount 20.0g
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8, 10, 12 and 24 h. At each time point, samples (5 ml) were with-
drawn from the receptor for detection and an equal amount
of the fresh receptor medium was added to keep a constant
volume.
2.7. Tissue distribution experiment
2.7.1. Experiment design
Skin, muscle and blood drug distribution in KM mice at dif-
ferent times was investigated in this experiment.The abdomen
hair of the mice was cut off carefully before the test. The
abdomen skin was cleaned with distilled water, and 100 mg
of the W/O ointment with BD-NLC was daubed on the surface
of skin. The area of skin applied ointment was 2.0 × 2.0 cm. Ad-
ministration duration of the self-made ointment was 2, 4, 6,
8, 12 and 24 h, respectively. The ointment was cleaned at each
time point using a cotton swab, except for the 24 h adminis-
tration sample, which was cleaned at 12 h. Finally, the ointment
on skin was cleaned up and the skin and muscle samples were
cut off after the mice were sacrificed. Four mice were used for
each time point in this test.
2.7.2. Sample extraction process
Skin and muscle cut from mice were weighed precisely and
divided into small pieces. 1.0 ml of methanol was added into
skin and muscle samples, respectively.The samples were under
sonicate procedure for 30 min and centrifuged at 16,000 rpm
for 5 min.
For the skin sample, 100 μl of the supernatant was mixed
with 100 μl of internal standard. The mixture was injected into
the HPLC system for analysis.
For the muscle sample, the supernatant was withdrawn and
evaporated to dryness under nitrogen at 40 °C.The residue was
reconstituted by 200 μl of methanol and vortex-mixed for 3 min.
The sample was centrifuged at 16,000 rpm for 5 min success-
fully. After that, 100 μl of internal standard was added into equal
volume of supernatant. Finally, the mixture was injected into
the HPLC system for analysis.
2.8. HPLC analysis
The concentration of BD was analyzed by HPLC. The HPLC
system consisted of a Hitachi L-2130 pump, a Hitachi L-2200
automatic injector and a Hitachi L-2400 ultraviolet detector.The
separation was performed on a Diamonsil C18 column
(200 × 4.6 mm, 5 μm, Dikma, China) with the flow rate of 1.0 ml/
min, and the detection wavelength was 239 nm. The mobile
phase was the mixture of methanol and water (80:20, v/v).
For the determination of BD in the receptor liquid, 200 μl
of the sample was mixed with equal volume of the internal
standard (itraconazole solution, 10 μg/ml). The volume of the
mixture for HPLC analysis was 20 μl.
For the determination of BD in skin and muscle, 100 μl of
the sample was mixed with equal volume of the internal stan-
dard (itraconazole solution, 5 μg/ml). 20 μl of the mixture was
injected into HPLC for analysis.
2.9. Skin irritation experiment
For topical ointment, skin irritation should be avoided. Rabbits
were used to detect the irritation of the self-made prepara-
tion.The skin irritation test was evaluated by the Draize method
[22]. The hair of two sides of the rabbits’ body was shaved 24 h
before test. Four groups of formulations were designed in this
experiment: SDS (sodium dodecyl sulfate, 10%, w/v); W/O oint-
ment with BD-NLC; W/O ointment with no-drug-NLC (blank
bases) and the mixture of BD and W/O ointment. SDS (0.5 ml)
and other groups (0.5 g) were smeared on the hairless skin of
the rabbits and removed 4 hours later. Finally, the reactions
of skin were inspected in the next 1, 24, 48 and 72 h.The degree
of erythema and edema were both recorded by the score of
dermal reactions. The score of 0 represented no erythema
or edema, the score of 1 represented very slight erythema or
edema, the score of 2 represented well-defined erythema or
edema, the score of 3 represented moderate to severe ery-
thema or edema, and the score of 4 represented severe
erythema or edema. The average score of every rabbit in every
day was calculated by Eq. 2.The category of irritation was scored
on the basis of the mean primary irritation index as follows:
0.0~0.4: negligible response
0.5~1.9: slight response
2.0~4.9: moderate response
5.0~8.0: severe response
Average score
score of erythema and edema
animal amounts o
=
×
∑
bserving times
(2)
3. Results and discussion
3.1. Preparation of BD loaded NLC
Precirol ATO 5 and OA were usually used as solid lipid and liquid
lipid in many researches of topically used NLC. Tween 80 was
chosen as the emulsifier in this experiment. The concentra-
tion of Tween 80 and different ratios of Precirol ATO 5:OA were
investigated in the in vitro skin penetration experiment. The
results are shown in Table 3. For topical preparations, high skin
Table 3 – In vitro skin penetration of BD-loaded NLC under different preparation conditions (n = 3, mean ± SD).
Formulation Concentration
of Tween 80 (%)
Precirol
ATO 5:OA
Penetration
(μg/ml)
Retention
(μg/g)
1 1.5 1:2 2.59 ± 0.50 228.07 ± 55.41
2 1.5 2:1 0.61 ± 0.03 112.02 ± 27.38
3 2.0 1:2 1.71 ± 0.18 312.83 ± 63.27
4 2.0 2:1 3.19 ± 0.74 219.55 ± 53.80
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retention and low penetration amount were expected. There-
fore, formulation 3 was chosen for the preparation of topical
ointment. The skin retention and skin permeation of BD was
312.83 μg/g and 1.71 μg/ml, respectively.
The results suggested that the formulations with 2.0% of
Tween 80 obtained higher skin retention of BD than formula-
tions with 1.5% of Tween 80. Obviously, the surfactant had an
effect in improving skin penetration properties. Tween 80 was
no longer added to optimize the formulation in case of any skin
irritation phenomenon.Therefore 2.0% of Tween 80 was chosen
for the further study. Subsequently, it could be seen that the
skin retention of the drug was improved with the increase of
OA loading. The liquid lipid in the lipid core of NLC was con-
ducive to the dissolution of drug from the carrier, whose
possible explanation could be that the addition of OA could
have created a less ordered skin penetration properties in solid
lipid matrix, resulting in the increase of drug loading in the
particles [23,24]. Furthermore, the lower melting point of OA
may be another reason for increasing drug retention.
3.2. Characterization of drug loaded NLC
The particle size, zeta potential, and EE of formulation 3 were
investigated. The results showed that the particle size and zeta
potential of BD loaded NLC were 169.1 nm (SD = 0.5) (PI = 0.195,
SD = 0.013) and −23.4 mv, respectively. In general, smaller par-
ticles (less than 200 nm) display more skin retention [25,26].
Zeta potential is a useful sign in controlling the stability of BD-
NLC, and an unstable system is usually accompanied by a
decrease in the value of zeta potential accelerating the ap-
proach of particles and formation of a particle aggregation [27].
An accepted arbitrary value for an incipient stable system that
separates low-charged surfaces from highly-charged sur-
faces is 20–25 mv [28]. The micrograph of TEM in Fig. 1
represented that the drug loaded NLC was in spherical shape.
The entrapment efficiency (EE%) of formulation 3 reached 85%,
which suggested that most of BD had been better entrapped
into the lipid matrix of NLC.
3.3. In vitro skin permeation of topical ointment
Carbopol emulgel ointment matrix and W/O ointment matrix
were selected as the NLC ointments for the preparation of the
final product. The results of in vitro skin permeation of the two
NLC ointments are represented in Table 4. The skin retention
of Carbopol emulgel ointment with BD-NLC and W/O oint-
ment with BD-NLC were 19.24 μg/g and 35.43 μg/g, respectively,
while skin penetration of the two preparations were 2.10 μg/
ml and 0.87 μg/ml, respectively. W/O ointment with BD-NLC
obtained higher skin retention and lower skin penetration
amount. Apparently, the W/O matrix was more appropriate for
the topical use of BD-loaded NLC.
3.4. In vitro drug release of NLC ointment
In vitro drug release experiment was designed to explain the
different transdermal results between the two topical oint-
ments. The results are presented in Fig. 2. The accumulated
release amount of BD in W/O ointment with BD-NLC in 24 h
was 10.04%, while the Carbopol ointment with BD-NLC was
7.60%. Obviously, the lipophilic W/O ointment matrix had better
release property than Carbopol NLC ointment (P < 0.05). When
the W/O ointment with BD-NLC was applied onto skin, both
W/O matrix and lipophilic drug could penetrate into SC. Since
the SC layer was lipophilic, the W/O matrix, BD and SC had
good affinity to each other. This further induced larger drug
Fig. 1 – Transmission electron micrograph of BD-loaded
NLC.
Table 4 – In vitro skin penetration of Carbopol emulgel
ointment with BD-NLC andW/O ointment with BD-NLC
(n = 3, mean ± SD).
Parameter Carbopol emulgel
ointment with
BD-NLC
W/O ointment
with BD-NLC
Penetration (μg/ml) 2.10 ± 0.25 0.87 ± 0.04
Retention (μg/g) 19.24 ± 3.80 35.43 ± 0.55
Fig. 2 – In vitro drug release of W/O ointment with BD-NLC
and Carbopol emulgel ointment with BD-NLC (n = 3,
mean ± SD).
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retention and lower penetration. Compared to W/O ointment
with BD-NLC, there was less BD released from Carbopol oint-
ment with BD-NLC. When the lipophilic drug was released from
the vehicle, the hydrophilic environment showed little affin-
ity to the drug. BD in the SC layer showed more tendencies to
pass through skin. As a result, Carbopol ointment with BD-
NLC showed much more skin penetration than W/O ointment
with BD-NLC.
3.5. Tissue distribution experiment
W/O ointment with BD-NLC was applied to the living mice in
the tissue distribution experiment. The results are presented
in Fig. 3. The amount of BD in skin tissue was much higher
than that in muscle. In 2 h and 4 h, a small amount of drug
could be detected in the muscle tissue. The active compound
retention in the skin increased with administration duration,
which suggested that self-made ointment had a good ten-
dency to be retained in the skin. Since the amount of drug
retained in the skin at 12 h and 24 h were 3.65 μg/g and 4.04 μg/
g, respectively, there was no significant difference between
them. On the other hand, a small amount of drug was de-
tected in the blood of mice in this experiment.
3.6. Skin irritation experiment
Skin irritation is an important side effect which should be con-
sidered for ointment for topical use. The results of rabbit skin
irritation test are shown in Fig. 4. The erythema and edema
could be observed apparently in rabbit skin of the positive
control group. The mean score of dermal observation of posi-
tive control was 5.25, which indicated moderate irritation. It
implied that the rabbit skin could reflect the actual condition
of the skin when the irritation occurred. There was no ery-
thema and edema of skin in the NLC ointment group within
72 h. The mixture of BD and ointment matrix induced slight
erythema with the score of 0.5625. Obviously, the results sug-
gested that when drug loaded into NLC, the skin irritation could
be decreased. From this perspective, NLC was a safe carrier in
dermal and transdermal drug delivery system.
4. Conclusion
The BD-loaded NLC was prepared by the melt emulsification
method for topical delivery of BD.The in vitro permeation study
showed that 2.0% of Tween 80 increased the skin retention of
BD. Meanwhile, when the proportion of Precirol ATO 5 and OA
was 1:2, the BD-NLC showed highest skin retention. W/O oint-
ment with BD-NLC exhibited higher skin retention (35.43 μg/
g) and lower skin penetration (0.87 μg/ml) than Carbopol
ointment with BD-NLC, respectively. In vitro drug release test
indicated that the W/O ointment with BD-NLC which could in-
crease skin retention was better for drug release. The self-
made topical ointment also showed desirable drug retention
in skin tissue of living mice and no skin irritation of rabbits.
In conclusion, this study will facilitate the development of BD-
NLC, which may improve skin retention, reduce the adverse
effects induced by systemic absorption and reduce skin
irritation.
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